Theme 3: reduced appetite and increased control of eating behaviours The most consistent theme emerging from the interviews was changes in eating behaviours
Based on the route of administration, the GLP-1 receptor agonist market is classified into parenteral and oral segments
The FDA said these and other companies had made false or misleading claims related to compounded versions of weight loss drugs
The model, beginning in 2026 for Medicaid and 2027 for Medicare, is voluntary for drug manufacturers, state Medicaid programs, and Medicare Part D plans
Despite the health benefits of weight-loss interventions like nutritional counseling, bariatric surgery, and medications like GLP-1 receptor agonists, utilization of obesity-related healthcare remains extremely low, especially by populations that are most affected by obesity
A few worry it might interfere with the medication itself